Sanuwave Health (NASDAQ:SNWV) Downgraded to Buy Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Sanuwave Health from a "strong-buy" to a "buy" rating, while other analysts maintained a positive outlook with a consensus rating of "Buy" and an average price target of $55.00.
• Sanuwave Health's shares are currently trading at $37.88, reflecting a decline of 2.0% recently, with a fifty-two week high of $46.58 and a low of $5.21.
• The company reported earnings of $0.01 EPS for the last quarter, surpassing analyst expectations, and had a revenue of $10.16 million, meeting estimates.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) was downgraded by Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report issued on Sunday.

A number of other research firms also recently weighed in on SNWV. Roth Capital lifted their price target on shares of Sanuwave Health from $54.00 to $55.00 and gave the stock a "buy" rating in a research note on Friday, August 22nd. Northland Capmk upgraded shares of Sanuwave Health to a "strong-buy" rating in a research report on Wednesday, September 3rd. Finally, Northland Securities started coverage on Sanuwave Health in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $55.00 price target for the company. One analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $55.00.

Sanuwave Health Stock Performance

Shares of SNWV traded up $0.17 on Friday, hitting $36.09. 30,797 shares of the stock traded hands, compared to its average volume of 38,505. The firm has a 50 day moving average price of $37.61. Sanuwave Health has a 1 year low of $5.63 and a 1 year high of $46.58.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.10. The company had revenue of $10.16 million during the quarter, compared to analyst estimates of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Institutional Investors Weigh In On Sanuwave Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in SNWV. Legal & General Group Plc purchased a new stake in shares of Sanuwave Health during the second quarter valued at $26,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Sanuwave Health in the 1st quarter valued at about $47,000. BNP Paribas Financial Markets acquired a new stake in Sanuwave Health in the 2nd quarter worth about $46,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Sanuwave Health during the 2nd quarter worth $52,000. Finally, New York State Common Retirement Fund purchased a new position in Sanuwave Health in the 2nd quarter worth approximately $102,000. Hedge funds and other institutional investors own 42.53% of the company's stock.

About Sanuwave Health

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.